Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study

J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):281-8. doi: 10.1097/QAI.0b013e31817bbbf0.

Abstract

Background: Alterations in serum lipids and an increased risk of myocardial infarction have been associated with HIV-1 infection and its treatment.

Methods: Lipoprotein subclasses were measured by nuclear magnetic resonance spectroscopy in frozen plasma samples from participants in the Multicenter AIDS Cohort Study. The effects of HIV-1 infection, antiretroviral therapy, and other factors on median particle concentrations were examined using quantile regression.

Results: Fasted samples were tested from 1082 men, including 609 HIV-seronegative and 473 HIV-1-infected men. Compared with HIV-seronegative men, HIV-1-infected men on antiretroviral therapy had an atherogenic phenotype with higher numbers of very low density lipoprotein and small low-density lipoprotein particles and lower numbers of high-density lipoprotein and large low-density lipoprotein particles. HIV-infected, antiretroviral-naive men had significantly lower high-density lipoprotein and small low-density lipoprotein particle concentrations compared with the HIV-seronegative men. Among men on antiretroviral therapy, the atherogenic phenotype was most pronounced in men with a good clinical status.

Conclusion: Use of antiretroviral therapy in HIV-1-infected men was associated with an "atherogenic lipoprotein phenotype."

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antiretroviral Therapy, Highly Active / adverse effects*
  • HIV Infections / blood*
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / adverse effects*
  • HIV-1*
  • Humans
  • Lipoproteins / blood*
  • Lipoproteins, LDL / blood
  • Lipoproteins, VLDL / blood
  • Male
  • Middle Aged
  • Ritonavir / pharmacology

Substances

  • HIV Protease Inhibitors
  • Lipoproteins
  • Lipoproteins, LDL
  • Lipoproteins, VLDL
  • Ritonavir